Approaches to conducting a physiologically relevant test (PRT) in the study of medicines containing substance IIc of the BCS subclass using sorafenib as an example

Autor: A. V. Suvorova, Yu. V. Medvedev, P. A. Losenkova, O. S. Kramarenko, E. A. Malashenko, A. M. Poluyanov, I. E. Shohin

Publikováno v: Разработка и регистрация лекарственных средств, Vol 13, Iss 3, Pp 176-185 (2024)

Introduction. Sorafenib is an antineoplastic drug belonging to class IIc according to the biopharmaceutical classification system (BCS) due to the presence of both acidic and basic properties. In addition to low solubility, sorafenib is characterized

Externí odkaz: https://doaj.org/article/f9432bbfce7f4c17baa107ecc3ecc108

Politicidio de baja intensidad: exterminio territorializado del Partido Revolucionario de los Trabajadores (PRT) en el Caribe colombiano, 1991-2005.

Autor: Mercado Vega, Armando José¹ amercado@utb.edu.co

Publikováno v: Colombia Internacional. Jul-Sep2022, Issue 111, p135-170. 36p.

PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox

Autor: A. V. Suvorova, P. A. Losenkova, Yu. V. Medvedev, E. A. Malashenko, I. E. Makarenko, A. M. Poluyanov, I. E. Shohin

Publikováno v: Разработка и регистрация лекарственных средств, Vol 13, Iss 3, Pp 166-175 (2024)

Introduction. Deferasirox is a complexing drug and belongs to class II according to the biopharmaceutical classification system (BCS), has acidic properties and belongs to subclass “a” (acid). This class is characterized by high permeability and

Externí odkaz: https://doaj.org/article/dbc1d4558e7042689e6d9613b3df9d1c

Response Aggregation to Obtain Truthful Answers to Sensitive Questions: Estimating the Prevalence of Illegal Purchases of Prescription Drugs.

Autor: Gregori, Marco (AUTHOR) marco.gregori@wbs.ac.uk, De Jong, Martijn G. (AUTHOR), Pieters, Rik (AUTHOR)

Publikováno v: Journal of Marketing Research (JMR). Oct2024, Vol. 61 Issue 5, p821-838. 18p.

Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3.

Autor: Hu, Yun¹ (AUTHOR), Paris, Sébastien² (AUTHOR), Sahoo, Narayan³ (AUTHOR), Wang, Qi⁴ (AUTHOR), Wang, Qianxia^3,5 (AUTHOR), Barsoumian, Hampartsoum B.¹ (AUTHOR), Huang, Ailing¹ (AUTHOR), Da Silva, Jordan² (AUTHOR), Bienassis, Célia² (AUTHOR), Leyton, Claudia S. Kettlun¹ (AUTHOR), Voss, Tiffany A.¹ (AUTHOR), Masrorpour, Fatemeh¹ (AUTHOR), Riad, Thomas¹ (AUTHOR), Leuschner, Carola¹ (AUTHOR), Puebla-Osorio, Nahum¹ (AUTHOR), Gandhi, Saumil¹ (AUTHOR), Nguyen, Quynh-Nhu¹ (AUTHOR), Wang, Jing⁴ (AUTHOR), Cortez, Maria Angelica¹ (AUTHOR), Welsh, James W.¹ (AUTHOR) Jwelsh@mdanderson.org

Publikováno v: Journal of Nanobiotechnology. 10/1/2024, Vol. 22 Issue 1, p1-22. 22p.